Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer
February 11, 2016 10:37 ET
|
Biofrontera AG
LEVERKUSEN, Germany, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from three pivotal Phase III trials for its lead drug...